Pipeline & Platform


PT003, Pearl’s lead combination new drug product candidate, is composed of the long-acting muscarinic antagonist (LAMA) glycopyrronium, and the long acting β2-agonist (LABA) formoterol fumarate, administered twice daily (BID) from an HFA-MDI. PT003 is the only LAMA/LABA combination product in late-stage development in a HFA MDI dosage formulation.


PT001 is Pearl's monotherapy Co-SuspensionTM Delivery Technology candidate containing the long-acting muscarinic antagonist (LAMA), glycopyrronium under evaluation to treat patients with COPD. Glycopyrronium is a highly potent bronchodilator. By leveraging the flexibility of Pearl’s Co-SuspensionTM Delivery Technology platform, the Company has been able to evaluate doses of PT001 as low as 600 nanograms in patients with COPD.

For more Pearl milestones, please click here.

1 - Formoterol fumarate has been approved for use in several forms for the treatment of patients with COPD, including Foradil® Aerolizer® (formoterol fumarate inhalation powder) by Schering-Plough and Novartis, Oxis® turbohaler® by AstraZeneca and SYMBICORT® (budesonide/formoterol fumarate dihydrate) by AstraZeneca.